Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice

Blood

Volumn 123, Issue 19, 2014, Pages 3045-3055

  Newman, Robert G ^a,b   Dee, Michael J ^b   Malek, Thomas R ^b   Podack, Eckhard R ^b   Levy, Robert B ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN GLYCOPROTEIN GP96 IG FUSION PROTEIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY S4B6; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; HEAT SHOCK PROTEIN; INTERLEUKIN 2;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER IMMUNIZATION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CROSS PRESENTATION; DRUG EFFICACY; HUMAN; HUMAN CELL; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOMA; LYMPHOMA CELL; MACROPHAGE; MINIMAL RESIDUAL DISEASE; MONOCYTE; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN SECRETION; SINGLE DRUG DOSE; TUMOR CELL INOCULATION; ANIMAL; C57BL MOUSE; HOST PATHOGEN INTERACTION; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; MICROBIOLOGY; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HEAT-SHOCK PROTEINS; HOST-PATHOGEN INTERACTIONS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOCYTE COUNT; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINATION;

EID: 84903130531     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-520775     Document Type: Article

References (89)

1. Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. 2013. Available at: http://www.cibmtr. org.
2. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010;10(3):213-221.
3. Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol. 1996;156(12):4609-4616. (Pubitemid 26174440)
4. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;110(2):185-192. (Pubitemid 34787355)
5. Hu H-M, Poehlein CH, Urba WJ, Fox BA. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 2002;62(14):3914-3919. (Pubitemid 34791051)
6. Ma J, Urba WJ, Si L, Wang Y, Fox BA, Hu H-M. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol. 2003;33(8):2123-2132. (Pubitemid 37010029)
7. Wang L-X, Li R, Yang G, et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 2005;65(22):10569-10577. (Pubitemid 41743752)
8. Keith MR, Levy RB. Transplant conditions determine the contribution of homeostatically expanded donor CD8 memory cells to host lymphoid reconstitution following syngeneic HCT. Exp Hematol. 2007;35(8):1303-1315. (Pubitemid 47088769)
9. Wrzesinski C, Paulos CM, Kaiser A, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010;33(1):1-7.
10. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA. 1986;83(10):3407-3411. (Pubitemid 16043046)
11. Udono H, Levey DL, Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci USA. 1994;91(8):3077-3081. (Pubitemid 24130178)
12. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 1995;269(5230):1585-1588.
13. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997;278(5335):117-120. (Pubitemid 27446289)
14. Janetzki S, Blachere NE, Srivastava PK. Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96. J Immunother. 1998;21(4):269-276.
15. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol. 2005;6(6):593-599. (Pubitemid 41710730)
16. Binder RJ, Kelly JB III, Vatner RE, Srivastava PK. Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins. J Immunol. 2007;179(11):7254-7261.
17. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway. Int Immunol. 2000;12(11):1539-1546.
18. Vabulas RM, Braedel S, Hilf N, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem. 2002;277(23):20847-20853. (Pubitemid 34967392)
19. Matzinger P, Bevan MJ. Induction of H-2-restricted cytotoxic T cells: in vivo induction has the appearance of being unrestricted. Cell Immunol. 1977;33(1):92-100. (Pubitemid 8182057)
20. Arnold D, Faath S, Rammensee H, Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med. 1995;182(3):885-889.
21. Yamazaki K, Nguyen T, Podack ER. Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection. J Immunol. 1999;163(10):5178-5182.
22. Strbo N, Yamazaki K, Lee K, Rukavina D, Podack ER. Heat shock fusion protein gp96-Ig mediates strong CD8 CTL expansion in vivo. Am J Reprod Immunol. 2002;48(4):220-225.
23. Oizumi S, Strbo N, Pahwa S, Deyev V, Podack ER. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes. J Immunol. 2007;179(4):2310-2317.
24. Oizumi S, Deyev V, Yamazaki K, et al. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells. J Immunother. 2008;31(4):394-401. (Pubitemid 351595162)
25. Schreiber TH, Deyev VV, Rosenblatt JD, Podack ER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res. 2009;69(5):2026-2033.
26. + cytotoxic T lymphocytes in the intestinal mucosa. Mucosal Immunol. 2010;3(2):182-192.
27. Strbo N, Vaccari M, Pahwa S, et al. Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. Vaccine. 2011;29(14):2619-2625.
28. Strbo N, Vaccari M, Pahwa S, et al. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J Immunol. 2013;190(6):2495-2499.
29. Raez LE, Walker GR, Baldie P, et al. CD8 T cell response in a phase I study of therapeutic vaccination of advanced NSCLC with allogeneic tumor cells secreting endoplasmic reticulum-chaperone gp96-Ig-peptide complexes. Advances in Lung Cancer. 2013;2(1):9-18.
30. Strbo N, Oizumi S, Sotosek-Tokmadzic V, Podack ER. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity. 2003;18(3):381-390. (Pubitemid 36351517)
31. Slavin S, Ackerstein A, Kedar E, Weiss L. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2. Bone Marrow Transplant. 1990;6(Suppl 1):86-90.
32. Ackerstein A, Kedar E, Slavin S. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood. 1991;78(5):1212-1215.
33. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006;311(5769):1924-1927.
34. Krieg C, Létourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA. 2010;107(26):11906-11911.
35. Létourneau S, van Leeuwen EMM, Krieg C, et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25. Proc Natl Acad Sci USA. 2010;107(5):2171- 2176.
36. + T cells to regulatory T cells. J Immunol. 2008;180(7):5118-5129.
37. Jin G-H, Hirano T, Murakami M. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. Int Immunol. 2008;20(6):783-789. (Pubitemid 351791522)
38. Borriello F, Sethna MP, Boyd SD, et al. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity. 1997;6(3):303-313. (Pubitemid 27148597)
39. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76(1):17-27. (Pubitemid 24035278)
40. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68(5):869-877.
41. Kägi D, Ledermann B, Bürki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994;369(6475):31-37. (Pubitemid 24144352)
42. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA. 2005;102(14):5126-5131.
43. Gorer PA. Studies in antibody response of mice to tumour inoculation. Br J Cancer. 1950;4(4):372-379.
44. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 1988;54(6):777-785.
45. + T cells. Blood. 2010;115(23):4934-4943.
46. Ross D, Jones M, Komanduri K, Levy RB. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(10):1430-1438.
47. Pope C, Kim S-K, Marzo A, et al. Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection. J Immunol. 2001;166(5):3402-3409. (Pubitemid 33117342)
48. Foulds KE, Zenewicz LA, Shedlock DJ, Jiang J, Troy AE, Shen H. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol. 2002;168(4):1528-1532. (Pubitemid 34135743)
49. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 2003;19(1):71-82. (Pubitemid 36859902)
50. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327(5966):656-661.
51. Blazar BR, Lees CJ, Martin PJ, et al. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J Immunol. 2000;165(9):4901-4909.
52. Ernst B, Lee D-S, Chang JM, Sprent J, Surh CD. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity. 1999;11(2):173-181. (Pubitemid 29428810)
53. + T cells in lymphopenic hosts. Immunity. 1999;11(2):183-190.
54. Kieper WC, Jameson SC. Homeostatic expansion and phenotypic conversion of naïve T cells in response to self peptide/MHC ligands. Proc Natl Acad Sci USA. 1999;96(23):13306-13311.
55. Murali-Krishna K, Ahmed R. Cutting edge: naive T cells masquerading as memory cells. J Immunol. 2000;165(4):1733-1737. (Pubitemid 30643121)
56. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med. 2000;192(4):557-564. (Pubitemid 30666256)
57. + dendritic cells in cytotoxic T cell immunity. Science. 2008;322(5904):1097-1100.
58. Toubai T, Sun Y, Luker G, et al. Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood. 2013;121(20):4231- 4241.
59. Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med. 2007;204(6):1405-1416. (Pubitemid 46919878)
60. Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol. 1997;159(7):3460-3473. (Pubitemid 127482105)
61. + T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity. Blood. 2004;103(10):3970-3978.
62. Prlic M, Kamimura D, Bevan MJ. Rapid generation of a functional NK-cell compartment. Blood. 2007;110(6):2024-2026. (Pubitemid 47443918)
63. Rapoport AP, Aqui NA, Stadtmauer EA, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011;117(3):788-797.
64. Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol. 2010;22(3):105-112.
65. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005;11(11):1230-1237. (Pubitemid 43093671)
66. Stadtmauer EA, Vogl DT, Luning Prak E, et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood. 2011;117(1):63-71.
67. Borrello I, Sotomayor EM, Rattis F-M, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versustumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood. 2000;95(10):3011-3019. (Pubitemid 30321148)
68. Jing W, Gershan JA, Johnson BD. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood. 2009;113(18):4449-4457.
69. + T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. Blood. 2011;117(25):6952-6962.
70. Hirokawa K, Sado T, Kubo S, Kamisaku H, Hitomi K, Utsuyama M. Intrathymic T cell differentiation in radiation bone marrow chimeras and its role in T cell emigration to the spleen. An immunohistochemical study. J Immunol. 1985;134(6):3615-3624. (Pubitemid 15034364)
71. Qian J, Wang S, Yang J, et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res. 2005;11(24 Pt 1):8808-8815. (Pubitemid 43005932)
72. Qian J, Hong S, Wang S, et al. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood. 2009;114(18):3880-3889.
73. Sato K, Torimoto Y, Tamura Y, et al. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood. 2001;98(6):1852-1857.
74. Iuchi Y, Torimoto Y, Sato K, et al. Combined use of dendritic cells enhances specific antileukemia immunity by leukemia cell-derived heat shock protein 70 in a mouse model with minimal residual leukemia cells. Int J Hematol. 2006;84(5):449-458. (Pubitemid 46061361)
75. Jimbo J, Sato K, Hosoki T, et al. Induction of leukemia-specific antibodies by immunotherapy with leukemia-cell-derived heat shock protein 70. Cancer Sci. 2008;99(7):1427-1434. (Pubitemid 351761734)
76. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195(3):327-333. (Pubitemid 34461490)
77. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med. 2002;195(3):335-341. (Pubitemid 34461491)
78. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195(3):343-351. (Pubitemid 34461492)
79. Harada M, Matsuzaki G, Shinomiya Y, et al. Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2. Cancer Immunol Immunother. 1994;38(5):332-338. (Pubitemid 24128012)
80. Courtney LP, Phelps JL, Karavodin LM. An anti-IL-2 antibody increases serum halflife and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacol. 1994;28(3):223-232. (Pubitemid 24316899)
81. Levin AM, Bates DL, Ring AM, et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature. 2012;484(7395):529-533.
82. Sato J, Hamaguchi N, Doken K, et al. Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy. 1993;6(3):225-231. (Pubitemid 23341325)
83. + T cells independently of the influx of monocytes into granulomatous lesions. J Exp Med. 1989;170(2):589-594.
84. Dunn PL, North RJ. Early gamma interferon production by natural killer cells is important in defense against murine listeriosis. Infect Immun. 1991;59(9):2892-2900.
85. Hamilton SE, Schenkel JM, Akue AD, Jameson SC. IL-2 complex treatment can protect naive mice from bacterial and viral infection. J Immunol. 2010;185(11):6584-6590.
86. + T effector-memory cells. J Immunol. 2012;189(9):4321-4330.
87. Younes A. A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2003;4(3):183-185. (Pubitemid 38128684)
88. Oki Y, McLaughlin P, Fayad LE, et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer. 2007;109(1):77-83. (Pubitemid 46120196)
89. Randazzo M, Terness P, Opelz G, Kleist C. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer. 2012;130(10):2219-2231.